The report titled “Protein Assay Market -Forecast to 2023″ is a direct appreciation by Market
Research Future of the market potential of the Protein Assay Market.
Market Highlights
The global Protein Assay Market is expected to witness considerable growth during the
forecast period, mainly due to the increasing investment by pharma and biotech companies
in research and development (R&D) and funding by governments of various countries for
proteomics research.
Protein Assay is an analytical technique used for measuring the concentration of protein in a
solution. These assays are one of the most extensively used procedures in life science
studies. Although, there is a wide range availability of protein assays, each assay is unique
in its own way and has its own merits and limitations, and hence a protein assay should be
selected considering their suitability for the application. For instance in Feb 2017, Promega
Corporation announced the development of a benchtop capillary electrophoresis (CE)
instrument in collaboration with Hitachi High-Technologies Corporation. These system are
equipped to carry NGS validation, PCR sizing and microsatellite analysis, single nucleotide
polymorphism, de novo sequencing and mutation detection.
Protein quantification is pivotal part of daily workflow of protein extraction in biochemistry
and molecular biology labs that involves protein extraction, analysis or labeling. Favorable
government policies for proteomics research, and the presence of a large number of players
in the global protein assay market are the key factors driving the growth of the market
during the forecast period.
Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/5091
Key Players:
Most Prominent key players in the Global Protein Assays Market are GE Healthcare (U.S.),
Thermo Fisher Scientific (U.S.), Bio-Rad Laboratories Inc. (U.S.), Merck KGaA (Germany),
Cell Signaling Technology Inc. (U.S.), Abcam plc (U.S.), Lucigen Corporation (U.S.),
PerkinElmer Inc. (U.S.), QIAGEN (Germany), Lonza Group Ltd. (Switerzland), Bio-Techne
(U.S.), BioVision Inc. (U.S.), Illumina Inc. (U.S.), New England Biolabs (U.S.), Takara Bio
Inc. (Japan), Promega Corporation (U.S.), F. Hoffmann-La Roche Ltd (Switerzland), and
others.
Market Updates:
Many new companies have jumped into the market in order to make the most out of the
opportunities. Companies are implementing the strategies of mergers and acquisitions with
other players. For instance, in June 2015, Thermo Fisher Scientific Inc. introduced the
Orbitrap Fusion Lumos Tribrid mass spectrometer and updated the device in 2017.
Segmentation:
The protein assays is segmented on the basis of type, application, product, technology and
end-users.
On the basis of type, the market is segmented into the copper-ion-based assays, test strip-
based assays, dye-binding assays, and others. On the basis of application, market is
segmented into diagnosis, drug discovery, protein purification and others. On the basis of
product, market is segmented into reagents & kits, instruments and others. On the basis of
technology market is segmented into colorimetric-based protein assays, fluorescence-based
protein assays, and absorbance-based protein assays. On the basis of end-user, the market
is segmented into hospitals & diagnostic centers, academic institutes, pharmaceutical &
biotechnology companies and others.
Regional Analysis:
Global protein assays consists of regions namely the Americas, Europe, Asia Pacific, and the
Middle East.
North America dominated the global protein assays market owing to the increasing research
and development in biotechnology and pharmaceutical companies especially for study of
genomics and proteomics play significant role in driving the global protein assays market.